Triple negative breast cancers (TNBC) still lack a targeted therapy, and targeting transcription factors, frequent drivers of malignancy in these cancers, is extremely difficult. Herein, we propose the development of a novel therapeutic approach for TNBC based on the use of the cutting-edge CRISPR/Cas9 technology to inhibit oncogenic transcription factors specific of TNBC. Specific guide RNAs for the transcription factor FOXC1 will be designed and complexed with recombinant protein Cas9, and their capacity to downregulate the target mRNA and protein levels will be confirmed by qRT-PCR and Western Blot. The biological effects of inhibiting FOXC1 will be investigated with functional assays. Genome-wide transcriptional and gene promoter occupancy changes will be analyzed by RNA Sequencing and ChIP Sequencing, respectively. Furthermore, CRISPR complexes will be encapsulated in liposomes targeted with tumour-specific peptides to provide a safe and effective delivery system. The in vivo biodistribution of CRISPR complexes upon systemic administration will be tested in organs and tumor ex vivo. The therapeutic effect of the CRISPR complexes will be investigated in orthotopic TNBC xenografts and patient-derived xenografts. The development of such therapy will provide a new targeted strategy with reduced side-effects for TNBC patients. This has the potential to reduce the mortality associated with these cancers while increasing the quality of life of the patients.
Cáncer de mama triple negativo
factor de transcripción
ribonucleoproteínas CRISPR/Cas9
FOXC1
Acción Estratégica en Salud (AES)
01/01/2022 - 31/12/2024
ANABEL, SOROLLA BARDAJI
INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)
INSTITUTO INV. BIOMEDICA DE LLEIDA. FUNDACION DR. PIFARRE (IRBLLEIDA)
CATALUÑA
LLEIDA
97,000 €